• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Do your heartworm protocols need an update?

February 11, 2019
Christopher Rehm, DVM
dvm360, dvm360 April 2019, Volume 50, Issue 4

Consider this your reminder postcard, folks. With new canine treatment guidelines out now, its a perfect time to revisit your protocols to make sure your veterinary practice is current on heartworm prevention and treatment for cats and dogs.

Whether you practice in Alabama, Arizona, California or Connecticut, chances are you have a protocol in place for routine heartworm screening and prevention as well as a plan to treat heartworm-positive dogs. But the American Heartworm Society-which continually monitors the latest studies-has recently updated guidelines. Check to see if you're up-to-date on ...

Preventives: Assessing risk.

The AHS heartworm guidelines on prevention call for year-round administration of heartworm preventives and practical steps to reduce mosquito exposure (for example, eliminating standing water and keeping dogs indoors during peak mosquito times) as the backbone of any prevention protocol. However, added risk may mean additional preventive steps are needed.

Down with heartworms!

Want to read more about new canine heartworm treatment guidelines?

  • American Heartworm Society releases 2018 canine heartworm guidelines​
  • Heartworm prevention: Don't take 'no' for an answer​
Advertisement
  • Counter cost concerns with heartworm treatment

Factors that constitute high risk include:

Heartworm prevalence. 

The relative risk of heartworm infection where you practice may vary both from year to year and from season to season. Take a year-over-year look at the number of heartworm cases you've been diagnosing. Has the number been rising? The presence of heartworm-positive dogs along with environmental and climate conditions that favor the proliferation of mosquitoes-either seasonally or year-round-can increase the risk of heartworm transmission.  

Client compliance. 

The efficacy of a prevention program is impaired by poor or inconsistent compliance. This also increases risk.

If and when the relative risk of heartworm transmission is considered high or individual client compliance is less than desirable, consider the added use of an EPA-approved repellent/ectoparasiticide. This will provide additional control of the mosquito vector and interrupt the chain of transmission by reducing the transmission from infected mosquitoes to dogs and from infected dogs to mosquitoes.

Testing: The ‘how' and ‘when' of heat treatment.

Heat treatment of serum samples prior to antigen tests can improve testing accuracy when antigen blocking produces false-negative results on in-clinic heartworm tests. While acknowledging that this added step has value when active clinical disease is suspected in the absence of a positive antigen test, however, the AHS does not recommend this step for routine in-clinic screening.

Why not? The available heartworm tests are highly sensitive and accurate. Heat treatment of samples is contrary to label instructions for in-house tests and may interfere with the accuracy of both heartworm tests and combination tests designed to detect antibodies of other infectious agents. 

Suspected serum samples should be sent to a veterinary reference lab or a college of veterinary medicine's parasitology department.

Treatment: Make the AHS protocol your go-to.

The step-by-step AHS heartworm treatment protocol-which includes administering a macrocyclic lactone (ML) preventive to kill juvenile worms and doxycycline to eliminate Wolbachia species bacteria prior to melarsomine administration-is designed to help reduce the severity of complications from adulticide therapy. The protocol includes a one-month waiting period between antibiotic and adulticide administration to allow more time for effects of the doxycycline to reduce worm biomass, reduce Wolbachia species metabolites and render microfilariae unable to mature to adults.

The AHS argues that this should be the default heartworm treatment. It's true that alternative non-arsenical protocols have been studied in the U.S. and Europe because of the need in cases where melarsomine treatment can't be used. However, the length of time required to kill adult worms, the uncertainty of “slow kill” treatment in resistance, the increased pathology, and the unknown restriction requirements with these protocols make them less than ideal for most patients and less predictable in outcomes. More studies are definitely needed.

Click here for a link to the full guidelines and other resources.

Christopher Rehm, DVM, is president of the American Heartworm Society and owner of Rehm Animal Hospitals in Mobile, Alabama.

download issueDownload Issue: dvm360 April 2019

Related Content:

MedicalProductsCardiologyTechniciansPractice OperationsOwnersParasitologydvm360 April 2019
Workplace bottlenecks in the LGBTQIA+ community
Workplace bottlenecks in the LGBTQIA+ community
The importance of safety, trust, and equity in the practice
The importance of safety, trust, and equity in the practice
Can our Pride panel answer these LGBTQ+ trivia questions?
Can our Pride panel answer these LGBTQ+ trivia questions?

Advertisement

Latest News

I graduated veterinary school in 2023: Here are my takeaways

Life after coming out in veterinary medicine

Free microchipping event to take place in Chicago

Zoo announces birth of critically endangered red wolf pups

View More Latest News
Advertisement